Gene-environment studies of asthma in Hispanic/Latino children
Recruitment Progress
Descriptive statistics for GALA I and GALA II study participants
GALA I | GALA II | SAGE II | ||||
---|---|---|---|---|---|---|
Descriptive Statistics |
Mexican |
Puerto Rican |
Latino case |
Latino control |
African American case |
African American control |
N | 294 | 365 | 2232 | 2228 | 908 | 616 |
N with mRNA | 0 | 0 | 1305 | 1022 | 372 | 327 |
Age, yr, median (25:75th quartiles) | 13.2 (11:20) | 11.9 (10:15) |
12.2 (10:15) |
13.4 (11:17) |
13.7 (11:17) |
15.9 (12:19) |
Sex, % male | 53.8 | 55.6 | 54.5 | 43.7 | 51.3 | 44.3 |
BMI, kg/m2, median (25:75th quartiles) | 23.7 (20:28) | 21.2 (17:26) |
22.3 (19:27) |
23.6 (20:28) |
23.2 (20:28) |
22.9 (20:27) |
Asthma Duration, yr, median (25:75th) | 7 (3:10) |
9 (7:12) |
9.2 (6:12) |
NA (NA:NA) |
9.8 (7:13) |
NA (NA:NA) |
Atopic eczema or allergic rhinitis, % | 81.4 | 84.9 | 79.9 | 30.9 | 84.8 | 27.4 |
Pulmonary Function |
||||||
Baseline FEV1 (% of predicted) | 90 (77:100) |
83 (74:93) |
91.4 (82:101) |
98.4 (91:108) |
82.3 (75:91) |
86.5 (80:94) |
Baseline FVC (% of predicted) | 97 (86:109) |
94 (83:105) |
94.8 (85:105) |
97.9 (90:108) |
87.3 (80:95) |
87.1 (81:94) |
Baseline FEV1/FVC (% of predicted) | 92 (87:99) |
90 (82:97) |
96.8 (91:102) |
101.6 (96:106) |
95.7 (89:101) |
99.5 (95:105) |
Max response to albuterol (% change) | 7.4 (4:12) | 4.8 (0.5:10) | 7.4(4:12) | 6.5(4:11) |